PCM
ORIC icon

Pentwater Capital Management’s Oric Pharmaceuticals ORIC Stock Holding History

Pentwater Capital Management’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-10,000
Closed -$339K – 372
2020
Q4 		$339K Buy
10,000
+2,000
+25% +$57.4K ﹤0.01% 212
2020
Q3 		$200K Hold
8,000
– – ﹤0.01% 213
2020
Q2 		$270K Buy
+8,000
New +$255K ﹤0.01% 143

Other funds holding ORIC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
CG
Column Group San Francisco, California $88.1M AUM 148.03% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Pentwater Capital Management's ORIC Position: Q1 2021 in Review

Pentwater Capital Management sold out of Oric Pharmaceuticals (ORIC) in Q1 2021, closing a stake of 10,000 shares — an estimated $339K sold.

Pentwater Capital Management first reported a position in ORIC in Q2 2020 and held it in 3 quarters. The position peaked at $339K in Q4 2020. 82 funds tracked by Wall St. Rank hold ORIC as of Q1 2021.

  • Pentwater Capital Management reported no remaining Oric Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • Pentwater Capital Management sold 10,000 Oric Pharmaceuticals shares in Q1 2021, an estimated $339K.
  • Pentwater Capital Management first reported a position in Oric Pharmaceuticals in Q2 2020 and held it in 3 quarters.
  • Pentwater Capital Management's Oric Pharmaceuticals position peaked at $339K in Q4 2020.
  • 82 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q1 2021.

Based on Pentwater Capital Management's 13F filing for Q1 2021, filed 17 May 2021.